Repare Therapeutics Inc. (RPTX)
| Market Cap | 152.80M |
| Revenue (ttm) | 68.68M |
| Net Income (ttm) | -68.52M |
| Shares Out | 42.45M |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,519 |
| Open | 3.440 |
| Previous Close | 3.430 |
| Day's Range | 3.330 - 3.600 |
| 52-Week Range | 2.710 - 8.490 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+177.78%) |
| Earnings Date | Nov 7, 2024 |
About RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company’s lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treat... [Read more]
Financial Performance
In 2023, Repare Therapeutics's revenue was $51.13 million, a decrease of -61.21% compared to the previous year's $131.83 million. Losses were -$93.80 million, 222.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for RPTX stock is "Strong Buy" and the 12-month stock price forecast is $10.0.
News
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor.
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting.
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers.
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will...
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expecte...
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio.
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Participate in Two Upcoming Investor Conferences.
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results...
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI.
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
BOSTON--(BUSINESS WIRE)--Foundation Medicine announces a collaboration with Repare Therapeutics to provide genomic profiling for Repare's ongoing Phase I/Ib MYTHIC study.
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patien...
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food an...
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of ...
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the ...
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results...
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debioph...
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
LAUSANNE, Switzerland & MONTREAL--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure ca...
Repare Therapeutics Appoints Steven H. Stein, M.D.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment ...
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $RPTX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repar...
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results...
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patien...
Repare Therapeutics to Regain Global Rights to Camonsertib
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will reg...
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that, under its ...
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate updat...
Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
LAUSANNE, Switzerland & MONTREAL--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure ca...